Tulopafant  (Synonyms: 妥洛帕泛; RP 59227)

Tulopafant is a platelet activating factor (PAF) antagonist.

Preincubation of neutrophils with Tulopafant (RP 59227) results in a concentration-dependent decrease in chemiluminescence produced by PAF primed cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs^[1].Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

425.50

C₂₅H₁₉N₃O₂S

116289-53-3

妥洛帕泛

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998 Oct;93(5):361-71.  [Content Brief]

  [2]. O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84.  [Content Brief]